drugset
drugset / Trial / NCT01257464

Sitagliptin in Cystic Fibrosis-Related Diabetes

NCT01257464 ↗

Phase 2 Terminated 3 enrolled University of British Columbia
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV) inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes (CFRD). We hypothesize that sitagliptin will improve meal-stimulated insulin secretion.

Timeline

Start
2010-09
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sitagliptin Small molecule 100 mg Oral

Indications

cystic fibrosis